BioPharma Dive – AI / Data
Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug
If consummated, the deal would hand Merck a treatment that could challenge Novartis’ fast-selling Scemblix. But the low purchase premium — which one analyst described as a “steal” — may leave room for a competing bid.